Betty Dong, PharmD

Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Residency School of Pharmacy
    University of California, San FranciscoPharm.D.1972 School of Pharmacy

    Collapse Research 
    Collapse Research Activities and Funding
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lopez MI, Cocohoba J, Cohen SE, Trainor N, Levy MM, Dong BJ. Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health. J Am Pharm Assoc (2003). 2019 Aug 09. PMID: 31405804.
      View in: PubMed
    2. Dong BJ, Williams MR, Bingham JT, Tokumoto J, Allen JD. Outcome of challenging HIV case consultations provided via teleconference by the Clinician Consultation Center to the Federal Bureau of Prisons. J Am Pharm Assoc (2003). 2017 Jul - Aug; 57(4):516-519. PMID: 28610939.
      View in: PubMed
    3. Dong BJ, Lopez M, Cocohoba J. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. J Am Pharm Assoc (2003). 2017 Jul - Aug; 57(4):510-515.e2. PMID: 28602784.
      View in: PubMed
    4. Goldschmidt RH, Chu C, Dong BJ. Initial Management of Patients with HIV Infection. Am Fam Physician. 2016 Nov 01; 94(9):708-716. PMID: 27929247.
      View in: PubMed
    5. Trang TP, Dong BJ, Kojima N, Klausner JD. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. Expert Opin Drug Saf. 2016 Sep; 15(9):1287-94. PMID: 27391203.
      View in: PubMed
    6. Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2014 Dec; 34(12):1341-54. PMID: 25359244.
      View in: PubMed
    7. Cocohoba J, Dong BJ, Johnson MO, Saberi P. Reporting of critical information in studies of pharmacists in HIV care. Int J Pharm Pract. 2014 Dec; 22(6):375-85. PMID: 24467531.
      View in: PubMed
    8. Medina MS, Plaza CM, Stowe CD, Robinson ET, DeLander G, Beck DE, Melchert RB, Supernaw RB, Roche VF, Gleason BL, Strong MN, Bain A, Meyer GE, Dong BJ, Rochon J, Johnston P. Center for the Advancement of Pharmacy Education 2013 educational outcomes. Am J Pharm Educ. 2013 Oct 14; 77(8):162. PMID: 24159203; PMCID: PMC3806946.
    9. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. PMID: 22301417; PMCID: PMC3506024.
    10. Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence. 2012; 6:297-322. PMID: 22536064; PMCID: PMC3333818.
    11. Sherman EM, Cocohoba JM, Neff SE, Dong BJ. Health care provider satisfaction with telephone consultations provided by pharmacists and physicians at the National HIV/AIDS Clinicians' Consultation Center. Ann Pharmacother. 2011 Dec; 45(12):1499-505. PMID: 22085777.
      View in: PubMed
    12. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther. 2008 Oct; 30(10):1747-65. PMID: 19014832.
      View in: PubMed
    13. Saberi P, Caswell NH, Gruta CI, Tokumoto JN, Dong BJ. Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. Ann Pharmacother. 2008 May; 42(5):621-6. PMID: 18413688.
      View in: PubMed
    14. Dong BJ, Cocohoba JM. Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother. 2006 Jul-Aug; 40(7-8):1311-21. PMID: 16788094.
      View in: PubMed
    15. Clay PG, Dong BJ, Sorensen SJ, Tseng A, Romanelli F, Antoniou T. Advances in human immunodeficiency virus therapeutics. Ann Pharmacother. 2006 Apr; 40(4):704-9. PMID: 16551767.
      View in: PubMed
    16. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov; 27(11):1725-51. PMID: 16368445.
      View in: PubMed
    17. Lim ML, Dong BJ, Hart SL. Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service. Pharmacotherapy. 2003 Sep; 23(9):1100-4. PMID: 14524642.
      View in: PubMed
    18. Goldschrnidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy. J Am Board Fam Pract. 2002 Jul-Aug; 15(4):319-31. PMID: 12150468.
      View in: PubMed